找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Diagnosis and Management of Myelodysplastic Syndromes; A Clinical Guide Aziz Nazha Book 2020 Springer Nature Switzerland AG 2020 HSCT.CHIP.

[复制链接]
查看: 16058|回复: 41
发表于 2025-3-21 16:07:31 | 显示全部楼层 |阅读模式
书目名称Diagnosis and Management of Myelodysplastic Syndromes
副标题A Clinical Guide
编辑Aziz Nazha
视频video
概述Presented in a concise, easy-to-read format.Features over 100 illustrations, photographs, and tables.Written by experts in the field
图书封面Titlebook: Diagnosis and Management of Myelodysplastic Syndromes; A Clinical Guide Aziz Nazha Book 2020 Springer Nature Switzerland AG 2020 HSCT.CHIP.
描述Myelodysplastic syndromes (MDS) are a group of clonal disorders characterized by pancytopenias and the risk of progression to acute myeloid leukemia. The diagnosis of MDS can be challenging, while the outcomes of MDS patients vary widely. This book provides a concise yet comprehensive overview of MDS..The book begins by reviewing the diagnostic workup of MDS, with a specific focus on the 2016 WHO criteria for MDS diagnosis, and the biology and pathophysiology of the disease. The text then presents the molecular landscape of MDS and its impact on disease diagnosis, prognosis, and treatment decisions. The book continues by profiling different prognostic models of MDS and concludes with a thorough review of treatment algorithms for lower and higher-risk MDS, as well as the use of hematopoietic stem cell transplant to combat the disease..Written by experts in the field, .Diagnosis and Management of Myelodysplastic Syndromes: A Clinical Guide. is a valuable resource for clinicians, practitioners, and researchers who are interested in MDS. The text also features over 100 illustrations, photographs, and tables. .
出版日期Book 2020
关键词HSCT; CHIP; CCUS; ICUS; azacitidine; decitabine; lenalidomide
版次1
doihttps://doi.org/10.1007/978-3-030-51878-3
isbn_softcover978-3-030-51880-6
isbn_ebook978-3-030-51878-3
copyrightSpringer Nature Switzerland AG 2020
The information of publication is updating

书目名称Diagnosis and Management of Myelodysplastic Syndromes影响因子(影响力)




书目名称Diagnosis and Management of Myelodysplastic Syndromes影响因子(影响力)学科排名




书目名称Diagnosis and Management of Myelodysplastic Syndromes网络公开度




书目名称Diagnosis and Management of Myelodysplastic Syndromes网络公开度学科排名




书目名称Diagnosis and Management of Myelodysplastic Syndromes被引频次




书目名称Diagnosis and Management of Myelodysplastic Syndromes被引频次学科排名




书目名称Diagnosis and Management of Myelodysplastic Syndromes年度引用




书目名称Diagnosis and Management of Myelodysplastic Syndromes年度引用学科排名




书目名称Diagnosis and Management of Myelodysplastic Syndromes读者反馈




书目名称Diagnosis and Management of Myelodysplastic Syndromes读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

1票 100.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 22:01:44 | 显示全部楼层
发表于 2025-3-22 03:11:47 | 显示全部楼层
发表于 2025-3-22 06:01:57 | 显示全部楼层
发表于 2025-3-22 08:43:36 | 显示全部楼层
发表于 2025-3-22 13:03:04 | 显示全部楼层
MDS Mimics Including CHIP, ICUS, and CCUSns or findings of low specificity. There exist several MDS “mimics” that share findings with MDS but are caused by more benign conditions, other neoplasms, or less well-characterized pre-malignant states. Vitamin and iron deficiencies need to be excluded along with autoimmune conditions, medication
发表于 2025-3-22 20:39:41 | 显示全部楼层
Prognostic Models in Myelodysplastic Syndromestools that take both patient (e.g., age, comorbidities) and disease characteristics (e.g., blast percentage, degree of cytopenias) into account have been developed and are the basis of clinical trial enrollment, patient counseling, and treatment recommendations. Among these clinical-pathologic scori
发表于 2025-3-22 22:57:54 | 显示全部楼层
Treatment Algorithms for Lower-Risk Myelodysplastic Syndromeerized by a low risk of progression to AML, but often prominent anemia. Prognosis of those patients can however be worsened by the presence of myelofibrosis, somatic mutations (except SF3B1 and TET2), resistance to first- and second-line treatments, and comorbidities..Anemia is generally the predomi
发表于 2025-3-23 03:23:03 | 显示全部楼层
Treatment Algorithms for Higher-Risk Diseasel care. While hypomethylating agents (HMAs) have proven clinical and survival benefit in these patients, the only curative treatment remains allogeneic hematopoietic stem cell transplant (HSCT). No regimen has clear superiority in relapsed or refractory higher-risk MDS, and clinical trials (particul
发表于 2025-3-23 07:12:36 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-8 00:02
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表